NovaBridge Biosciences (NBP): Cash & Equivalents
Older than the company's other figures. The latest Cash & Equivalents is for the year ended 2023-12-31, while the company's latest annual report covers the year ended 2025-12-31. Its later filings do not report this line under the concept TickerFacts maps.
2.14B CNY
As of 2023-12-31
-23.4%
3-year compound annual growth
+6.2%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2023-12-31 | 2.14B CNY | -33.4% | 2024-04-30, Balance as of period end |
| 2022-12-31 | 3.21B CNY | -8.8% | 2024-04-30, Balance as of period end |
| 2021-12-31 | 3.52B CNY | -26.0% | 2023-05-01, Balance as of period end |
| 2020-12-31 | 4.76B CNY | +318.4% | 2022-04-29, Balance as of period end |
| 2019-12-31 | 1.14B CNY | -28.4% | 2021-04-28, Balance as of period end |
| 2018-12-31 | 1.59B CNY | n/a | 2020-04-29, Balance as of period end |